Pharmaceutical

AHA 2024: lerodalcibep provides promising results in open-label extension trial, LIBERATE-OLE

At AHA 2024, clinical trial results were presented from the ongoing open-label extension trial, LIBERATE-OLE, involving lerodalcibep.

Nov 19, 2024 - 06:00
AHA 2024: lerodalcibep provides promising results in open-label extension trial, LIBERATE-OLE
At AHA 2024, clinical trial results were presented from the ongoing open-label extension trial, LIBERATE-OLE, involving lerodalcibep.
Read the original article

Tags:

Previous Article

AHA 2024: Plozasiran demonstrates promising Phase III results in FCS adults

Next Article

EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Generative AI – beyond the hype

Generative AI – beyond the hype

Jul 3, 2023

STAT+: In a showy hearing, Bernie Sanders gets few answers about lower drug prices

STAT+: In a showy hearing, Bernie Sanders gets few answ...

Feb 11, 2024

FDA AdCom votes in favour of Stealth’s Barth syndrome drug

FDA AdCom votes in favour of Stealth’s Barth syndrome drug

Oct 12, 2024